Effect of a Combination Cream Containing 4% Tranexamic Acid, 3% Nicotinamide, 1% Hyaluronic Acid, and 1% Lactobacillus on MASI Scores in Patients with Melasma
Article metrics
OJS usage and citation sourcesViews and downloads are recorded by OJS; statistics processing may be delayed. A dash means the source count is unavailable. Search Google Scholar
Article Sidebar
Ivani, Prasetyadi Mawardi, Nurrachmat Mulianto (2026). Effect of a Combination Cream Containing 4% Tranexamic Acid, 3% Nicotinamide, 1% Hyaluronic Acid, and 1% Lactobacillus on MASI Scores in Patients with Melasma. Journal of Pharmaceutical and Sciences, JPS Volume 9 Nomor 3 (2026). https://doi.org/10.36490/journal-jps.com.v9i3.1635
Main Article Content
Abstract
Melasma is a chronic recurrent hyperpigmentation disorder characterized by brownish-to-gray facial patches that may negatively affect patients' quality of life. Its multifactorial pathogenesis involves ultraviolet radiation, hormonal influences, genetic predisposition, inflammation, and oxidative stress, highlighting the need for therapies targeting multiple biological pathways. This study aimed to evaluate the effect of a combination cream containing 4% tranexamic acid, 3% nicotinamide, 1% hyaluronic acid, and 1% Lactobacillus on Melasma Area and Severity Index (MASI) scores in patients with melasma. A double-blind randomized controlled trial was conducted in 28 subjects randomly allocated into two groups (combination cream, n=14; modified Kligman's formula, n=14) using computer-generated randomization. The primary outcome was the MASI score, while treatment safety, assessed from local skin reactions, was evaluated as a secondary outcome. Evaluations were performed at weeks 2, 4, 6, and 8 using MASI scores. Pre- and post-treatment analyses were conducted using repeated measures ANOVA and Friedman's test, while between-group comparisons were performed using an independent t-test. The combination cream group demonstrated a reduction in MASI score from 12.90±5.47 to 6.62±3.00 at week 8 (mean change ΔMASI = −6.28) , although statistical significance was not reached (p=0.054). The modified Kligman's formula group showed a significant reduction in MASI score from 13.94 to 7.93 at week 8 (mean change ΔMASI = −6.01) (p<0.001). Comparative analysis demonstrated no significant differences between groups regarding MASI score improvement (p>0.05). Local skin reaction scores were consistently lower in the combination cream group from week 4 to week 8 (all p≤0.004). The combination cream showed a trend toward MASI improvement that did not differ significantly from the modified Kligman's formula, with a more favourable tolerability profile
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Doolan B, Gupta M. Melasma. Aust J Gen Pract. 2021;50(12):880–5.
Mpofana N, Chibi B, Gqaleni N, Hussein A, Finlayson AJ, Kgarosi K, et al. Melasma in people with darker skin types: a scoping review protocol on prevalence, treatment options for melasma and impact on quality of life. Syst Rev. 2023;12(1):139.
Yang W, Meng X, Liu T, Chen N, Li D, Xu Y. The Exposome in Melasma: A Comprehensive Review of Etiology, Mechanisms, and Implications for Management. Clin Cosmet Investig Dermatol. 2026;19:594944.
Zhou X, Du HH, Ni L, Ran J, Hu J, Yu J, et al. Nicotinamide Mononucleotide Combined With Lactobacillus fermentum TKSN041 Reduces the Photoaging Damage in Murine Skin by Activating AMPK Signaling Pathway. Front Pharmacol. 2021;12:643089.
Espósito ACC, Cassiano DP, da Silva CN, Lima PB, Dias JAF, Hassun K, et al. Update on Melasma-Part I: Pathogenesis. Dermatol Ther (Heidelb). 2022;12(9):1967-88.
Chen Y, Vellaichamy G, Schneider SL, Kong W, Liu Z. Exposure factors in the occurrence and development of melasma (Review). Exp Ther Med. 2024;27(4):131.
Gu D, Pan R, Meng X, Liu T, Zhong H, Chen N, et al. What lies behind melasma: a review of the related skin microenvironment. Int J Dermatol. 2025;64(2):256-65.
Miao F, Wan J, Zhou Y, Shi Y. Unraveling Melasma: From Epidermal Pigmentation to Microenvironmental Dysregulation. Biology (Basel). 2025;14(10):1402.
Verma K, Dasuri V, Friedmann D. Melasma in the United States: A Cross-sectional Study of Prevalence Data Using the All of Us Database. J Dermatol Dermatol Surg. 2023;27:76–7.
Viorizka PBB, Setyaningrum T, Qurnianingsih E, Damayanti. The Profile and Triggering Factors of Melasma Patients: A Retrospective Study. BIKKK. 2023;35:142–7.
Devi AK, Utomo B, Indramaya DM, Listiawan MY, Sawitri, Murtiastutik D, et al. Profile of melasma patients in dermatology and venerology outpatient clinic Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Bali Med J. 2022;11:166–73.
Menul A, Umborowati R. Retrospective Study: Diagnosis and Therapy of Melasma Patients. BIKKK. 2014;26(1):56-63.
Al Dhafiri M, Almutairi M, Alutaibi HM, Aldandan HR, Albshr FA, Alkhalifa FS. Attitude Toward Using the Triple Combination Bleaching Formula and Related Outcomes: A Cross-Sectional Study. Cureus. 2021;13(12):e20542.
Prathyoosha S, Ananditha K, Narayana Rao T, Gopal KVT, Krishnam Raju PV. A Randomized Study to Evaluate the Efficacy of Oral Tranexamic Acid, Modified Kligman's Formula, and Placebo Cream in Melasma. Indian Dermatol Online J. 2024;15(5):787-93.
Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral Tranexamic Acid for the Treatment of Melasma: A Review. Dermatol Surg. 2018;44(6):814-25.
Desai S, Ayres E, Bak H, Manco M, Lynch S, Raab S, et al. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation. J Drugs Dermatol. 2019;18(5):454-9.
Siquier-Dameto G, Boisnic S, Boadas-Vaello P, Verdú E. Anti-Aging and Depigmentation Effect of a Hyaluronic Acid Mechanically Stabilized Complex on Human Skin Explants. Polymers (Basel). 2023;15(11):2438.
Tsai WH, Chou CH, Chiang YJ, Lin CG, Lee CH. Regulatory effects of Lactobacillus plantarum-GMNL6 on human skin health by improving skin microbiome. Int J Med Sci. 2021;18(5):1114-20.
Fusco A, Perfetto B, Savio V, et al. Regulatory Ability of Lactiplantibacillus plantarum on Human Skin Health by Counteracting In Vitro Malassezia furfur Effects. J Fungi (Basel). 2023;9(12):1153.
Bertold C, Fontas E, Singh T, Gastaut N, Ruitort S, Pugliese SW, et al. Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24-week double-blind prospective randomized controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2601-7.
Sarkar R, Yadav V, Yadav T, P J, Mandal I. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol. 2025;64(6):992-1004.
Lee CY, Choi BM, Kim DS, Choi H, Hong H, Chi WJ, et al. Anti-Inflammatory and Skin-Lightening Activities of Exosomes Derived from Latilactobacillus sakei BK-5 Isolated from Aster koraiensis Flowers. J Microbiol Biotechnol. 2025;35:e2511022.
Cha SY, Woo IK, Cha YJ, Lee NK, Jang HJ, Paik HD. Anti-melanogenic and Antioxidant Activities of Lactiplantibacillus plantarum Strains in Skin Cells via the CREB/MITF and Nrf2/HO-1 Pathways. Probiotics Antimicrob Proteins. 2025;17(6):3795-810.
Ghasemiyeh P, Haghighi NF, Dastgheib L, Ranjbar S, Mohammadi-Samani S. Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial. Sci Rep. 2025;15(1):42739.
Passeron T, Kerob D, Le Dantec G, Demessant-Flavigny AL, Nascimento ARD, Moura R, et al. Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial Melasma. Dermatol Ther (Heidelb). 2025;15(9):2379-90.